WEGOVY FLEXTOUCH 1.7MG INJ

Distributor inventory | Injection

Chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity; may be used in adolescents ≥12 years with obesity as per prescribing information/physician advice

Semaglutide is a GLP-1 receptor agonist that increases satiety, reduces hunger and food intake, and helps control appetite. It also slows gastric emptying and improves glucose regulation, supporting sustained weight loss when used with lifestyle changes.

Subcutaneous injection once weekly on the same day each week, at any time of day, with or without food. Inject into abdomen, thigh, or upper arm; rotate injection sites. Follow the dose-escalation schedule prescribed; do not use if solution is cloudy/colored or contains particles. If a dose is missed, take within 5 days; otherwise skip and take next dose on the scheduled day.

Nausea, vomiting, diarrhoea, constipation, abdominal pain, decreased appetite, dyspepsia, gastro-oesophageal reflux, belching, headache, dizziness, fatigue, injection-site reactions

Prescription-only medicine. Contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Risk of pancreatitis—stop and seek medical care if severe persistent abdominal pain occurs. May cause gallbladder disease (gallstones/cholecystitis). Can cause dehydration and worsen kidney function, especially with severe GI symptoms. Monitor for hypoglycaemia when used with insulin or sulfonylureas; dose adjustment of those agents may be needed. Not recommended in severe gastrointestinal disease (e.g., gastroparesis). Monitor for diabetic retinopathy complications in patients with diabetes. Rare risk of allergic reactions. Not indicated for type 1 diabetes; not for use with other GLP-1 receptor agonists or weight-loss products unless directed by a doctor.